Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_assertion type Assertion NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_head.
- NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_assertion description "[A total of 471 treatment-naive patients with histologically proven chronic hepatitis C virus (HCV) infection (106 with cirrhosis; 185 with HCV genotype 1 [HCV-1], 157 with HCV genotype 2 [HCV-2], 92 with HCV genotype 3 [HCV-3] and 37 with HCV genotype 4 [HCV-4]) were consecutively treated with PEG-IFN-alpha2b 1.5 microg weekly and weight-based RBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_provenance.
- NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_assertion evidence source_evidence_literature NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_provenance.
- NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_assertion SIO_000772 19578243 NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_provenance.
- NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_assertion wasDerivedFrom befree-20150227 NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_provenance.
- NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_assertion wasGeneratedBy ECO_0000203 NP977920.RAZuylhCX9jidYCl9a_J8AY9jrSf3OG-QZAM58Hh_aRjM130_provenance.